Ximelagatran
As of the edition of 20 October 2026, Ximelagatran is a small molecule: withdrawn from the market in 2006; acts on F2.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Withdrawn from market, 2006
- Kind
- Small molecule
- Withdrawn from market
- 1 January 2006 (worldwide)
- Registered trials
- 2, 2 stopped early
- Disease areas
- Heart and blood vessels
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Target
| Gene | Protein | UniProt |
|---|---|---|
| F2 | Prothrombin | P00734 |
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase 2 | 1 | 0 | 0 | 1 |
| Phase 3 | 1 | 0 | 0 | 1 |
| All trials | 2 |